This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England.
One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
Chemotherapy‐induced alopecia (CIA) represents perhaps the most distressing side effect of chemotherapeutic agents and is of huge concern to the majority of patients. Scalp cooling is currently the only safe option to combat CIA. Clinical and biological evidence suggests improvements can be made, including efficacy in delivering adequately‐low temperature to the scalp and patient‐specific cap design. The increased use of scalp cooling, an understanding of how to deliver it most effectively and biological evidence‐based approaches to improve its efficacy have enormous potential to ease the psychological burden of CIA, as this could lead to improvements in treatment and patient quality‐of‐life.
> Neoadjuvant 5‐fluorouracil, oxaliplatin, and lapatinib in combination with radiation therapy is safe for neoadjuvant treatment for patients with localized human epidermal growth receptor 2‐positive esophagogastric adenocarcinoma.
> Evaluation of this drug combination in a larger patient pool would allow for more accurate analysis of its efficacy.